Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 57
Filter
1.
Radiol Case Rep ; 19(8): 3394-3399, 2024 Aug.
Article in English | MEDLINE | ID: mdl-38841600

ABSTRACT

Fibrosing mediastinitis is a rare entity generally caused by granulomatous disease. Most cases develop as a complication of histoplasmosis. Association with tuberculosis has been rarely documented. We report the case of 3 young patients who presented with superior vena cava syndrome several years after treated tuberculosis. Biological, radiological, and histological investigations led to the diagnosis of fibrosing mediastinitis.

2.
Ann Med Surg (Lond) ; 86(6): 3713-3716, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38846868

ABSTRACT

Introduction and importance: Adrenal insufficiency is a rare chronic disease with a prevalence of 39 to 60 cases per million peoples in Europe. However, the prevalence is higher in sub-saharian Africa. The occurrence of pregnancy in adrenal insufficiency is rare but associated with high maternal and perinatal morbidity and mortality. For this reason, the management of pregnancy in adrenal insufficiency patient must be provided by a multidisciplinary team. Case presentation: The authors report the case of a 34-year-old pregnant woman followed for adrenal insufficiency secondary to prolonged corticosteroid therapy. Treatment consisted to an obstetrical and endocrinological follow-up and corticosteroid replacement therapy with hydrocortisone. A prophylactic cesarean section at 38 weeks resulted in the birth of a newborn male weighing 3395 g. Maternal and perinatal prognosis was good. Clinical discussion: Pregnancy in adrenal insufficiency is a therepeutic challenge in developing countries. Through this case, the authors discuss the therapeutic and prognostic aspects of adrenal insufficiency in our setting. Conclusion: With the introduction of gluco-corticosteroid replacement therapy, pregnancy in adrenal insufficiency can progress normally.

3.
Rev Prat ; 74(5): 533-536, 2024 May.
Article in French | MEDLINE | ID: mdl-38833238

ABSTRACT

WHAT ARE THE INDICATIONS FOR CORTICOSTEROID THERAPY IN COPD? In stable state chronic obstructive pulmonary disease (COPD), inhaled corticosteroids (ICS) should be used in case of frequent exacerbation only, associated with long-term bronchodilators including long-acting beta-agonist (LABA) and long-acting muscarinic antagonist (LAMA). When frequent exacerbations persist despite dual inhaled therapy (LABA + CSI or LABA+LAMA), triple inhaled therapy (LAMA+LABA+CSI) is indicated. In COPD exacerbation, the level of evidence for systemic corticosteroids is very low, justifying not to systematically prescribe systemic corticosteroids and when used to restrict this use to short-term (5 days) and low doses.


QUELLES SONT LES INDICATIONS POUR LA CORTICOTHÉRAPIE DANS LA BPCO ? Dans la bronchopneumopathie chronique obstructive (BPCO) à l'état stable, les corticostéroïdes inhalés (CSI) ne sont à utiliser qu'en cas d'exacerbations fréquentes, en association avec des bronchodilatateurs de longue durée d'action de type bêta-2-agoniste de longue durée d'action (LABA) et anticholinergique de longue durée d'action (LAMA). En cas de persistance d'exacerbations fréquentes malgré une bithérapie inhalée (LABA-CSI ou LAMA-LABA), une triple thérapie (LAMA-LABA CSI) peut être proposée. En cas d'exacerbation de BPCO, le niveau de preuve de la corticothérapie systémique est faible, justifiant ne pas recourir à ce traitement de façon systématique ou de le réaliser en cures courtes (cinq jours) et à faibles doses quand il est prescrit.


Subject(s)
Pulmonary Disease, Chronic Obstructive , Humans , Pulmonary Disease, Chronic Obstructive/drug therapy , Administration, Inhalation , Adrenal Cortex Hormones/therapeutic use , Adrenal Cortex Hormones/administration & dosage , Bronchodilator Agents/therapeutic use , Bronchodilator Agents/administration & dosage , Drug Therapy, Combination , Glucocorticoids/therapeutic use , Glucocorticoids/administration & dosage
4.
Radiol Case Rep ; 19(2): 768-772, 2024 Feb.
Article in English | MEDLINE | ID: mdl-38089140

ABSTRACT

Sarcoidosis is a benign multisystem granulomatosis of unknown etiology. The mediastino-hilar sphere is a preferred site for the disease. It can sometimes reveal a confusing pseudotumoral presentation, constituting a diagnostic trap to be considered. We report the case of a 56-year-old woman whose lesional process rapidly resolved after 2 months of corticosteroid therapy.

5.
Cureus ; 15(10): e47031, 2023 Oct.
Article in English | MEDLINE | ID: mdl-37965407

ABSTRACT

We report a case of a 34-year-old male with severe multisystemic involvement (including the testis, musculoskeletal system, skin, upper respiratory tract, ocular system, peripheral nerves, abdomen, and kidney) due to granulomatosis with polyangiitis (GPA) and a high proteinase 3 (PR3)-antineutrophil cytoplasmic antibodies (PR3ANCA) titer. A renal biopsy showed pauci-immune glomerulonephritis (GN). Systemic corticotherapy combined with cyclophosphamide was chosen for induction therapy. During the induction phase, clinical deterioration occurred in the form of severe alveolar hemorrhage, leading to admission to the intensive care unit (ICU). Influenza A (H1N1) was detected in the respiratory tract. Furthermore, blood sampling revealed an invasive Klebsiella pneumoniae infection that persisted despite multiple antibiotic regimens. A CT scan showed splenic vascular compromise, assumed to be the primary source of the infection, with sustained improvement after splenectomy. Maintenance therapy included a tapering dose of corticotherapy for 36 months and azathioprine 100mg daily for five years, which achieved full and sustained remission. The patient has been in full remission for nine years, with mild renal sequelae, including proteinuria and secondary hypertension.

6.
Cureus ; 15(12): e50596, 2023 Dec.
Article in English | MEDLINE | ID: mdl-38222121

ABSTRACT

We report the case of a 42-year-old immunocompetent Indian patient presenting with miliary tuberculosis complicated by respiratory failure requiring intubation. Conventional quadritherapy was initiated for wild-type Mycobacterium tuberculosis. On day 29 of antibiotic treatment, persistent fever and neurological deterioration prompted the diagnosis of multiple brain and medullary tuberculomas, some surrounded by edema. Laboratory investigations ruled out meningitis and subtherapeutic drug concentrations. To enhance cerebrospinal fluid penetration, ethambutol was replaced with levofloxacin on day 30, and rifampicin doses were increased to 30 mg/kg. Dexamethasone was introduced on day 30 to address the paradoxical response to antituberculosis therapy, but neurological deterioration persisted, leading to hemiparesis and coma, with concurrent development of acute respiratory distress syndrome. As salvage therapy, an anti-tumor necrosis factor agent, infliximab (IFX), was administered on day 40. Rapid clinical improvement was observed, marked by awakening and subsequent weaning from respiratory ventilation just eight days after the first IFX infusion. The patient was discharged from the intensive care unit 10 days post-IFX initiation, with steroids discontinued one month after IFX introduction. Both antituberculosis treatment and IFX infusions (seven in total) were maintained for one year. Clinical and radiological evaluation at one year demonstrated complete clinical and radiological recovery.

7.
Cureus ; 14(12): e32833, 2022 Dec.
Article in English | MEDLINE | ID: mdl-36570116

ABSTRACT

Aspergillus is a ubiquitous fungus whose clinical manifestations and prognosis after infection depend on the host's immune status. The disease can have an insidious course, making it a challenging diagnosis that should be considered in patients with risk factors. We report the case of a 78-year-old man with a known history of asthma-chronic obstructive pulmonary disease (COPD) overlap syndrome and idiopathic pulmonary fibrosis on long-term therapy with high-dose oral corticosteroids, hypertension, dyslipidemia, type 2 diabetes, and hypo coagulated atrial fibrillation. He was admitted to the Emergency Department (ED) for dyspnea, productive cough, and wasting syndrome. Recent hospitalization due to pneumonia of the left upper lobe (LUE) with no agent isolation is worth mentioning, treated with levofloxacin. Due to slow improvement, he underwent bronchoscopy (BFC), which revealed friable bronchial mucosa, with isolation of Candida albicans in bronchial secretions (BS) but without evidence of neoplastic cells in the pathological anatomy (PA). He completed 14 days of itraconazole. He was discharged after partial clinical improvement. One week later, he was again admitted to a medical ward because of worsening respiratory symptoms and wasting syndrome. Laboratory findings included an elevated C-reactive protein (CRP) and sedimentation rate, hypoosmolar hyponatremia, hypoproteinemia, and hypoalbuminemia. The study of hyponatremia revealed the syndrome of inappropriate secretion of antidiuretic hormone (SIADH), and the persistence of respiratory symptoms led us to perform a chest computed tomography (CT), which revealed a subsegmental LUE atelectasis. Due to suspicion of neoplasia, he repeated BFC with isolation of Aspergillus on the bronchoalveolar lavage (BAL) and PA. Subacute invasive pulmonary aspergillosis (IPA) was assumed and voriconazole was started. However, he had an unfavorable evolution with marked cachexia and hemorrhagic shock due to lower gastrointestinal bleeding as a complication of hypocoagulation resulting in death. Chronic exposure to corticosteroids and structural lung disease are recognized risk factors for Aspergillus infection. The presentation as a wasting syndrome associated with respiratory symptoms and SIADH raised suspicion for neoplasia, which was excluded. The PA was fundamental for the definitive diagnosis of IPA. The fatal outcome, probably attributable to late diagnosis, reinforces the importance of high clinical suspicion for Aspergillus infection in patients with risk factors.

8.
Clín. investig. ginecol. obstet. (Ed. impr.) ; 49(1): 1-5, Enero-Marzo, 2022. ilus
Article in Spanish | IBECS | ID: ibc-203213

ABSTRACT

La mastitis granulomatosa idiopática es una rara enfermedad que afecta sobre todo a mujeres jóvenes. Supone un importante desafío diagnóstico y terapéutico al presentarse en ocasiones como una lesión mamaria indicativa de malignidad. No se conoce su etiología ni existen pruebas de imagen que permitan diagnosticar con certeza la enfermedad, requiriendo de un estudio anatomopatológico para confirmar el diagnóstico. El tratamiento puede ir desde la mera observación, pasando por la toma prolongada de corticosteroides orales, hasta la cirugía. Dado que esta dolencia es infrecuente en la práctica clínica, no existen protocolos unificados acerca del mejor tratamiento y seguimiento de las pacientes. Presentamos un caso de mastitis granulomatosa idiopática diagnosticado en nuestro centro, así como el tratamiento propuesto y el seguimiento realizado. Por último, revisamos la literatura existente en relación con esta infrecuente entidad.


Granulomatous mastitis is an uncommon disease that primarily affects young women. It represents a diagnostic and therapeutic challenge, as it might be confused with breast carcinoma. There are no mammographic or ultrasonographic findings that correlate imaging features with histological results. Therapeutic management of this disease can range from simple observation to long-term corticosteroid treatment or surgery. Because granulomatous mastitis is infrequent in clinical practice, there are no standardised protocols regarding the best treatment and follow-up for these patients. We present the case of a women diagnosed in our department, and her treatment and follow-up. We also selectively examine the available literature to support our case.


Subject(s)
Humans , Female , Young Adult , Health Sciences , Granulomatous Mastitis , Diagnosis , Drug Therapy , Gynecology , Breast Diseases , Adrenal Cortex Hormones
9.
Pan Afr Med J ; 43: 196, 2022.
Article in French | MEDLINE | ID: mdl-36942131

ABSTRACT

Idiopathic granulomatous mastitis (IMD) is a chronic benign inflammatory disease of the breast which can mimic breast cancer. It is more common in young women of childbearing age and poses a challenge in diagnosis of inflammatory breast tumor. We report the case of a 26-year-old female patient who presented with inflammatory breast. Clinical examination showed apyretic patient with edematized and painless irregular smooth mass in the left breast measuring 4 cm surmounted by crusts and multiples fistulizing scars discharging pus by applying pressure, with mobile ipsilateral axillary adenopathy. The remainder of the physical examination showed inflammatory erythematous patches on both legs. A mammogram plus breast ultrasound was performed followed by biopsy that objectified fibrous mastopathy. Lumpectomy was performed due to the persistence of symptoms. Anatomopathological examination objectified granulomatous mastitis. Etiological research didn't identify a clear cause. Corticotherapy associated with antibiotic therapy was started with complete regression of symptoms after two months.


Subject(s)
Breast Diseases , Breast Neoplasms , Erythema Nodosum , Granulomatous Mastitis , Female , Humans , Adult , Granulomatous Mastitis/complications , Granulomatous Mastitis/diagnosis , Erythema Nodosum/etiology , Erythema Nodosum/complications , Breast/pathology , Breast Neoplasms/diagnosis
10.
Cureus ; 14(12): e33076, 2022 Dec.
Article in English | MEDLINE | ID: mdl-36721548

ABSTRACT

We present a case of severe pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a 63-year-old woman needing venous oxygenation by an extracorporeal membrane. Given the difficult clinical resolution with persistent inflammatory parameters, treatment with corticosteroids (methylprednisolone) was prescribed. The clinical evolution observed, namely the improvement of respiratory and imaging parameters, reiterates the recommendations of corticosteroids for moderate to severe disease.

11.
Clin. biomed. res ; 42(4): 369-377, 2022. ilus
Article in English | LILACS | ID: biblio-1513216

ABSTRACT

Corticosteroid therapy to combat inflammation caused by SARS-CoV-2 seems to be a risk factor for developing secondary fungal co-infections. PubMed and ScienceDirect databases were searched, with the following word groups: [(aspergillosis OR mucormycosis OR candidiasis) AND (coronavirus disease) AND (corticoids). The selected articles present the main risk factors related to the establishment of secondary fungal co-infections in COVID-19 patients. Corticosteroid therapy used to combat inflammation caused by SARS-CoV-2 has been shown to be strongly associated with the establishment of mucormycosis and aspergillosis. Mucormycosis has been the main fungal co-infection related to corticosteroid therapy, causing a high number of deaths in COVID-19 patients. Diabetes mellitus was the most prevalent comorbidity, especially for the establishment of mucormycosis. Dexamethasone use seems to be associated with mucormycosis emergence and death. However, aspergillosis showed a greater relationship with patient recovery. Thus, risk factors such as diabetes mellitus, combined with corticosteroid use, have shown a relationship to the establishment of mucormycosis. The corticosteroids used in COVID-19 patients should be individually analyzed, considering the patient's medical history and the risk/benefit ratio of the use of these drugs.


Subject(s)
Adrenal Cortex Hormones/adverse effects , COVID-19/complications , COVID-19 Drug Treatment/adverse effects , Aspergillosis/drug therapy , Coinfection/drug therapy , Mucormycosis/drug therapy
12.
Acta Endocrinol (Buchar) ; 17(2): 248-250, 2021.
Article in English | MEDLINE | ID: mdl-34925575

ABSTRACT

A young Caucasian woman presents several episodes of severe fasting hypoglycemia. Fasting lab tests revealed: glycemia 28 mg/dL, insulinemia 143.3 µU/mL, insulin antibodies above 100 U/mL, leading to the diagnosis of insulin autoimmune syndrome. Due to lack of clinical improvement after 2 months, prednisone was started at 0.5 mg/kg/day, and then tapered by 5 mg every 5 days. Three weeks after discontinuing corticotherapy, the patient had no more severe fasting hypoglycemia, but occasionally postprandial mild hypoglycemia. Fasting lab tests showed: glycemia 83 mg/dL, insulinemia 58.6 µU/mL. At 5 hours during oral glucose tolerance test glycemia was 33 mg/dL, insulinemia 152.9 µU/mL.

13.
Inflammopharmacology ; 29(6): 1819-1827, 2021 Dec.
Article in English | MEDLINE | ID: mdl-34825303

ABSTRACT

BACKGROUND: Rheumatoid arthritis is an inflammatory disease with joint manifestations. In the presence of extra-articular manifestations, the morbidity and severity of the disease increase. Glucocorticoid is used as a treatment and may result in side effects related to cardiovascular risk. METHODS: This was a cross-sectional study including 59 volunteers with rheumatoid arthritis receiving treatment at a hospital of Campos Gerais that aimed to establish the relation between cardiovascular risk, glucocorticoid treatment and myeloperoxidase in these patients. Subjects were divided into two groups: using (n = 39) and without glucocorticoids (n = 20). They underwent clinical evaluation, physical examination and blood samples were taken. Statistical analysis was performed using Student's t test and Mann-Whitney test. Logistic regression was performed to assess the cardiovascular risk. The significance level was 5% (α = 0.05). Calculations were performed using the Statistical Package for the Social Science version 21.0. RESULTS: There has been a significant difference between groups in blood glucose values (p = 0.012), which can be explained by the different percentage of diabetic patients in the groups. When assessing cardiovascular risk using the predictors of glucocorticoid dose, time of glucocorticoid use, myeloperoxidase, and C-reactive protein together, these were responsible for significantly predicting this risk (p = 0.015). CONCLUSION: A significant relation between the predictor myeloperoxidase alone was also demonstrated (p = 0.037), it may be an important predictor of cardiovascular risk among individuals with rheumatoid arthritis.


Subject(s)
Arthritis, Rheumatoid/drug therapy , Cardiovascular Diseases/epidemiology , Glucocorticoids/administration & dosage , Peroxidase/metabolism , Adult , Aged , Blood Glucose/metabolism , C-Reactive Protein/metabolism , Cardiovascular Diseases/etiology , Cross-Sectional Studies , Dose-Response Relationship, Drug , Female , Glucocorticoids/adverse effects , Heart Disease Risk Factors , Humans , Male , Middle Aged , Time Factors
14.
Rev Prat ; 71(6): 587-596, 2021 06.
Article in French | MEDLINE | ID: mdl-34553543

ABSTRACT

Side effects of long-term oral corticosteroid therapy. Systemic corticosteroid therapy has been used for over 70 years, and is still the cornerstone of the treatment of many conditions, in particular systemic, autoimmune or inflammatory diseases. Side effects of corticosteroids are numerous, and for most of them well known by prescribers. Nonetheless, guidelines for the prevention of corticosteroids toxicity are scarce, and the implementation of protective measures by prescribers is heterogenous. Hence, corticosteroids related complications entail a significant morbidity, which, importantly, could be largely prevented. We conducted therefore a systematic literature, through the Medline database, the Cochrane database and the grey literature until January 2021. After recalling the history of the discovery of corticosteroid therapy and its main pharmacological properties, we present the various complications associated with long-term corticosteroid therapy, and discuss the relevance of the preventive measures that may be proposed in daily practice in the light of available scientific evidence. This work highlights the importance of multidisciplinary follow-up, but above all of a thorough screening of the risk factors of complications at treatment initiation, and of a repeated evaluation of the complications all along the treatment course, in order to reduce the significant burden of morbidity associated with long-term corticosteroid therapy and to improve patient quality of life.


Effets indésirables de la corticothérapie orale au long cours. La corticothérapie systémique est utilisée depuis plus de 70 ans et reste la pierre angulaire du traitement de nombreuses affections. Ses effets indésirables sont nombreux et, pour la plupart, bien connus. Pour autant, les recommandations concernant leur prévention sont parfois manquantes, et souvent hétérogènes, y compris dans leur mise en œuvre par les prescripteurs. De ce fait, les complications induites par la corticothérapie sont à l'origine d'une morbidité importante, la plupart du temps évitables. Nous avons donc réalisé une revue systématique de la littérature, à travers les bases Medline, Cochrane et la littérature grise, jusqu'à janvier 2021. Après avoir rappelé l'histoire de la découverte de la corticothérapie et ses principales caractéristiques pharmacologiques, nous présentons les différentes complications associées à une corticothérapie au long cours et les mesures de prévention disponibles, en discutant leur efficacité et leur pertinence à la lumière des recommandations actuelles ou, à défaut, des dernières données scientifiques disponibles. Ce travail met en évidence l'importance du suivi multidisciplinaire des patients traités par corticothérapie systémique au long cours, mais surtout celle d'un dépistage préalable des facteurs associés à la survenue de complications et de réévaluations répétées de ces complications sous traitement, afin de diminuer le poids très important de la morbidité qui y est associée et ainsi d'améliorer la qualité de vie des patients.


Subject(s)
Adrenal Cortex Hormones , Quality of Life , Adrenal Cortex Hormones/adverse effects , Glucocorticoids/adverse effects , Humans
15.
Exp Ther Med ; 22(4): 1096, 2021 Oct.
Article in English | MEDLINE | ID: mdl-34504550

ABSTRACT

Primary immune thrombocytopenia (ITP) is characterized by isolated low platelet count and it is a diagnosis of exclusion, contrasting to secondary ITP. Therefore, a positive diagnosis is difficult and requires extensive investigation. Some of the underlying conditions that are associated with ITP are lymphoproliferative disorders and infections, especially viral ones. In the present study, the case of a patient diagnosed with diffuse large B-cell lymphoma, who received chemotherapy and autologous hematopoietic stem cell transplantation is presented. After a complete remission of four years, the patient presented with sudden intense hemorrhagic syndrome and severely decreased platelet count. The most frequent causes of secondary ITP were excluded, including lymphoma relapse, and intravenous corticosteroids were started. However, shortly after hospital admission, the patient developed neuro-psychiatric anomalies, fever and pancytopenia, and West-Nile encephalitis was diagnosed. Although the initial development was favorable, he started to complain of progressive severe muscle weakness and eventually succumbed to infectious complications in the setting of prolonged hospitalization, corticotherapy, and immobilization.

16.
Exp Ther Med ; 22(3): 1043, 2021 Sep.
Article in English | MEDLINE | ID: mdl-34373729

ABSTRACT

Since the first appearance of coronavirus disease 2019 (COVID-19), multiple studies have focused on this novel coronavirus. Within a few months, the clinical and paraclinical manifestations and the mechanisms by which these changes are induced were elaborated. Clinically, the virus mainly causes the common cold, but can also result in severe or fatal pneumonia/acute respiratory syndrome. Regarding the biological changes, similar to any other virus, it can lead to a reduced lymphocyte count. The second most common change is represented by a reduced thrombocyte count. Furthermore, most patients have blood clotting abnormalities, inflammatory syndrome, raised D-dimer and lactate dehydrogenase levels. Detection of immune thrombocytopenia in asymptomatic patients who tested positive for COVID-19 justifies the need to perform differential diagnosis and testing for COVID-19. Typically, patients with severe forms of COVID-19 develop mild thrombocytopenia, while severe thrombocytopenia is rarely reported. The aim of this case report was to present the situation in which one asymptomatic patient who tested positive for COVID-19 developed severe immune thrombocytopenia.

18.
J Wound Care ; 30(3): 184-190, 2021 Mar 02.
Article in English | MEDLINE | ID: mdl-33729847

ABSTRACT

OBJECTIVE: There are few means to treat large keloid scars, as exeresis-even if partial-impedes direct closure without tension in the absence of a flap or a skin graft. This study evaluates the efficacy, indications for use and limitations of a new therapeutic protocol, combining an extralesional keloid excision left to heal by secondary intention with a paraffin dressing and glucocorticoid ointment, followed by monthly intrascar injections of corticosteroids upon full re-epithelialisation. METHOD: A retrospective study of patients treated for keloid scars by using the new therapeutic protocol. Scars were categorised as either healed or recurring. Their recurrence was scored according to the changes in functional signs and the scar volume. RESULTS: A total of 36 scars were studied. The mean follow-up was 14.1 months. Healing occurred in a mean of 6.8 weeks. The mean surface area was 21.6cm2. Healing rate was 30.5%. Scar volume was improved in 60% of recurrent cases and functional signs in 56%. Based on adherence with the corticotherapy, two patient groups could be discerned. For patients in the 'adherent' group, the healing rate was 40%, and scar volume was improved in 75% of recurrent cases and the functional signs in 83% of cases. CONCLUSIONS: The healing rate in this study was close to that reported in the literature. Excision-healing by secondary intention could therefore be offered to patients for whom adherence is uncertain. The protocol in this study offers a straightforward, fast, accessible solution that does not appear to entail any risk of additional keloids. It could potentially offer a treatment option in case of failure of other treatments, large keloid scars or scalp keloids.


Subject(s)
Cicatrix/therapy , Glucocorticoids/therapeutic use , Keloid/therapy , Surgical Flaps , Wound Healing , Cicatrix/surgery , Humans , Keloid/pathology , Retrospective Studies , Treatment Outcome
19.
Prog Urol ; 31(5): 243-244, 2021 04.
Article in French | MEDLINE | ID: mdl-33468416
SELECTION OF CITATIONS
SEARCH DETAIL
...